Entera Bio (ENTX) Stock Price, News & Analysis

Company Overview

Entera Bio, Inc. is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis. EB613 entered Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics in healthy volunteers. In parallel, Entera Bio is advancing EB612, an oral tumor necrosis factor (TNF) antagonist, toward early‐stage clinical development for inflammatory diseases such as rheumatoid arthritis and Crohn’s disease.

Since its founding in 2010, Entera Bio has established operations in Newton, Massachusetts, and research facilities in Israel, positioning the company at the intersection of North American and international biopharmaceutical innovation. Its leadership team combines expertise in peptide chemistry, clinical development, regulatory affairs and commercial strategy. Entera Bio plans to collaborate with established pharmaceutical partners to support late‐stage clinical programs and the global commercialization of its oral peptide product candidates.

Key Stats

• Today's Range: $1.21 to $1.29
• 50-Day Range: $1.00 to $1.37
• 52-Week Range: $0.91 to $3.22
• Volume: 69,586 shs
• Average Volume: 191,377 shs
• Market Capitalization: $63.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Entera Bio Stock Analysis - MarketRank™

Entera Bio scored higher than 80% of companies evaluated by MarketBeat, and ranked 148th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Entera Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Entera Bio has a consensus price target of $9.00, representing about 611.5% upside from its current price of $1.27.

Amount of Analyst Coverage

Entera Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Entera Bio are expected to decrease in the coming year, from ($0.34) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entera Bio is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entera Bio is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Entera Bio has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.41% of the float of Entera Bio has been sold short.

Short Interest Ratio / Days to Cover

Entera Bio has a short interest ratio ("days to cover") of 1.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entera Bio has recently decreased by 5.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entera Bio does not currently pay a dividend.

Dividend Growth

Entera Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.93

News Sentiment

Entera Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Entera Bio this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for ENTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.1 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Entera Bio in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $38,300.00 in company stock, which represents 0.0615% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Entera Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,300.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.38% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

14.11% of the stock of Entera Bio is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 5/29/2026
• Next Earnings (Estimated): 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTX
• CIK: 1638097
• Web: www.enterabio.com
• Phone: (722) 532-7151
• Fax: N/A
• Employees: 20
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Entera Bio: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +595.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.44 million
• Net Margins: N/A
• Pretax Margin: -27,235.71%
• Return on Equity: -83.31%
• Return on Assets: -70.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.93
• Quick Ratio: 7.93

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 1,593.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 5.89

Miscellaneous

• Outstanding Shares: 49,220,000
• Free Float: 44,115,000
• Market Cap: $63.74 million
• Optionable: Optionable
• Beta: 1.54